Literature DB >> 1331054

Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents.

C N Chang1, V Skalski, J H Zhou, Y C Cheng.   

Abstract

2',3'-Dideoxy-3'-thiacytidine (cis-(+/-)-SddC) was found to have potent activity against hepatitis B virus and human immunodeficiency viruses in culture. Recent studies by us identified (-)-SddC as the stereoisomer responsible for the antiviral effect and showed that the cytotoxicity was mainly caused by (+)-SddC. Metabolism studies showed that these drugs were converted to their monophosphates, diphosphates, and triphosphates. The enzyme responsible for the formation of monophosphates was identified to be cytoplasmic deoxycytidine kinase in CEM cells. Uptake studies showed that the intracellular concentration of (-)-SddC and its metabolites was approximately 5-fold higher than that of (+)-SddC metabolites. (-)-SddCTP was more potent than (+)-SddCTP in inhibiting hepatitis B virus replication; (+)- and (-)-SddCTP exhibited minimal inhibition on polymerases alpha and delta, more inhibition on beta, and strong inhibition on gamma. In all cases, (+)-SddCTP was found to be more inhibitory than (-)-SddCTP to all four polymerases. (+)-SddCMP competed with dCTP for incorporation into DNA by DNA polymerase gamma and beta and served as a chain terminator; however, similar incorporation was not detected using other polymerases. The selective inhibition of DNA synthesis in isolated mitochondria by (+)- and (-)-SddCTP suggests a stereospecificity on the mitochondrial uptake of deoxynucleoside triphosphates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331054

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

Authors:  J M de Muys; H Gourdeau; N Nguyen-Ba; D L Taylor; P S Ahmed; T Mansour; C Locas; N Richard; M A Wainberg; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity?

Authors:  A Verri; A Montecucco; G Gosselin; V Boudou; J L Imbach; S Spadari; F Focher
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.

Authors:  Jin-Yang He; Yu-Tong Zhu; Rui-Yi Yang; Li-Ling Feng; Xing-Bo Guo; Feng-Xue Zhang; Hong-Shan Chen
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

5.  Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.

Authors:  Jeremiah W Hanes; Kenneth A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

6.  Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphosphate as substrate.

Authors:  F Focher; G Maga; A Bendiscioli; M Capobianco; F Colonna; A Garbesi; S Spadari
Journal:  Nucleic Acids Res       Date:  1995-08-11       Impact factor: 16.971

7.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors:  K P Fischer; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.

Authors:  P Hafkemeyer; A Keppler-Hafkemeyer; M A al Haya; M von Janta-Lipinski; E Matthes; C Lehmann; W B Offensperger; S Offensperger; W Gerok; H E Blum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 9.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11.

Authors:  O Turriziani; J D Schuetz; F Focher; C Scagnolari; J Sampath; M Adachi; F Bambacioni; E Riva; G Antonelli
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.